Characterization of monocyte-derived IFNα-generated dendritic cells

被引:9
作者
Jacobs, B. [1 ]
Wuttkel, M. [1 ]
Papewalis, C. [1 ]
Fenk, R. [2 ]
Stuessgen, C. [1 ]
Baehring, T. [1 ]
Schinner, S. [1 ]
Raffel, A. [3 ]
Seissler, J. [4 ]
Schott, M. [1 ]
机构
[1] Univ Hosp Duesseldorf, Dept Diabet Endocrinol & Rheumatol, D-40228 Dusseldorf, Germany
[2] Univ Hosp Duesseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[3] Univ Hosp Duesseldorf, Dept Gen & Visceral Surg, Dusseldorf, Germany
[4] Univ Munich, Med Clin Innenstadt, Munich, Germany
关键词
dendritic cells; natural killer cells; interferon alpha; CD56; cytotoxicity; vaccination;
D O I
10.1055/s-2007-1022564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antitumor effects of IFN alpha is mainly mediated by the activation of cytotoxic T lymphocytes (CTLs), the activation of natural killer (NK) cells, and the generation of highly potent antigen-presenting dendritic cells (IFN-DCs). Recently, we demonstrated that these cells partially express the NK cell marker CD56 and reveal a direct cytotoxic immunity towards tumor cells. The aim of the present study was to explore these cells in more detail with respect to their phenotypical and functional characteristics. Flowcytometric analyses revealed that a 5-day incubation time of CD14+ monocytes with IFN alpha results in a steady increase of CD56 surface expression of these cells from 25% (+/-2%) on day 1 up to 68% (+/-11 %) on day 5. Interestingly, additional culturing of negatively selected CD56- IFN-DCs also resulted in a partial CD56 surface expression. By comparing both cell types in more detail we found a significant decrease of CD14 expression on CD56+ IFN-DCs (66 +/- 6%) compared to CD56- IFN-DCs (76 +/- 6%). On the basis of functional tests, CD56+ IFN-DCs revealed a slightly increased phagocytosis capacity compared to CD56- IFN-DCs as only 82% of CD56- IFN-DCs showed a positive intracytoplasmatic signal after 60 minutes coculturing with FITC-labeled albumin, whereas 91 % of CD56+ IFN-DCs were positive. Moreover, CD56+ IFN-DCs revealed a stronger T cell stimulation capacity compared to CD56- IFN-DCs. These results together with our previously described data suggest that CD56+ IFN-DCs and CD56-IFN-DCs may represent one identical cell population with different maturation status rather than two separate cell entities. Because of their high stimulating capacity and their direct cytolytic effects these cells represent a new promising tool for cellular anticancer therapy.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 18 条
[1]   Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon [J].
Banchereau, J ;
Ueno, H ;
Dhodapkar, M ;
Connolly, J ;
Finholt, JP ;
Klechevsky, E ;
Blanck, JP ;
Johnston, DA ;
Palucka, AK ;
Fay, J .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) :505-516
[2]   Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].
Fanger, NA ;
Maliszewski, CR ;
Schooley, K ;
Griffith, TS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1155-1164
[3]   Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL [J].
Griffith, TS ;
Wiley, SR ;
Kubin, MZ ;
Sedger, LM ;
Maliszewski, CR ;
Fanger, NA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) :1343-1353
[4]   CYTOKINE THERAPEUTICS - LESSONS FROM INTERFERON-ALPHA [J].
GUTTERMAN, JU .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1198-1205
[5]   Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection [J].
Kolumam, GA ;
Thomas, S ;
Thompson, LJ ;
Sprent, J ;
Murali-Krishna, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (05) :637-650
[6]   Type I interferons keep activated T cells alive [J].
Marrack, P ;
Kappler, J ;
Mitchell, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (03) :521-529
[7]   IFN-α skews monocyte differentiation into toll-like receptor 7-expressing dendritic cells with potent functional activities [J].
Mohty, M ;
Vialle-Castellano, A ;
Nunes, JA ;
Isnardon, D ;
Olive, D ;
Gaugler, B .
JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3385-3393
[8]  
PAPEWALIS C, 2008, IN PRESS J IMMUNOL, V180
[9]   Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma [J].
Papewalis, Claudia ;
Fassnacht, Martin ;
Willenberg, Holger S. ;
Domberg, Julia ;
Fenk, Roland ;
Rohr, Ulrich-Peter ;
Schinner, Sven ;
Bornstein, Stefan R. ;
Scherbaum, Werner A. ;
Schott, Matthias .
CLINICAL ENDOCRINOLOGY, 2006, 65 (02) :215-222
[10]   Expression of CCR-7, MIP-3β, and Th-1 chemokines in type IIFN-induced monocyte-derived dendritic cells:: importance for the rapid acquisition of potent migratory and functional activities [J].
Parlato, S ;
Santini, SM ;
Lapenta, C ;
Di Pucchio, T ;
Logozzi, M ;
Spada, M ;
Glammarioli, AM ;
Malorni, W ;
Fais, S ;
Belardelli, F .
BLOOD, 2001, 98 (10) :3022-3029